Chronic liver disease (CLD) is a major global health concern, accounting for approximately 2 million deaths annually worldwide [1]. Despite the advances in managing CLD over the past decade, CLD-related mortality has steadily increased in the United States (US) [2,3]. With the global pandemic of coronavirus disease-2019 (COVID-19), individuals with CLD represent a vulnerable population at higher risk for complications, including mortality [4]. During the early COVID-19 pandemic (until December 2020), the management of COVID-19 was prioritized in the hospital, negatively impacting the care of CLD [5].
